Information Provided By: 
Fly News Breaks for February 3, 2020
AYX
Feb 3, 2020 | 06:21 EDT
Piper Sandler analyst Brent Bracelin raised his price target for Alteryx to $144 from $112 while keeping a Neutral rating on the shares. Channel feedback points to another strong quarter across the company's partners and enterprise customers, Bracelin tells investors in a research note. However, the analyst believes tough compares could weigh on Alteryx's 2020 and 2021 outlook.
News For AYX From the Last 2 Days
AYX
Apr 23, 2024 | 08:31 EDT
New option listings for April 23rd include Express Inc (EXPRQ). Option delistings effective April 23rd include PGT Innovations Inc (PGTI), NGM Biopharmaceuticals Inc (NGM), Karuna Therapeutics Inc (KRTX), KINNATE BIOPHARMA INC (KNTE), Daseke Inc (DSKE), Tritium Dcfc Ltd (DCFC), Xtrackers MSCI All China Equity ETF (CN), CymaBay Therapeutics Inc (CBAY), Alteryx Inc (AYX), XTRACKERS MSCI CHINA A INCLUSION EQUITY ETF (ASHX), Recro Pharma, Inc. (SCTL), Splunk Inc (SPLK), and Textainer Group Holdings Limited (TGH).
